EPHA2 and breast carcinoma: EphA2 was used as for antibody-based targeting because high levels of EphA2 expression are found on the most aggressive tumor cells and in the case of this study MDA-MB-231 was used as they are a model for more aggressive and hormone-independent form of breast cancer [23, 25].